Rapid plaque clearance with anti-amyloid therapy for Alzheimer’s disease: in consideration of donanemab treatment duration from real-world cases

Sep 8

Written by Fanny Elahi

Fibronectin mediates APOE4-driven blood–brain barrier dysfunction in Alzheimer’s disease

Potential contributors to variable penetrance of NOTCH3 p.Arg1231Cys Variant